ODC1 and triple-negative breast carcinoma: Treatment with a dual inhibitor of A1R and ornithine decarboxylase 1, ODC-MPI-2, increased cAMP levels and reduced polyamine production, ultimately leading to growth inhibition in triple-negative breast cancer (TNBC) cell lines [66].